Financial Data and Key Metrics Changes - Third quarter revenue was $1.6 billion, with adjusted EBITDA of $518 million, representing an adjusted EBITDA margin of 32.3% [13][30] - The company is lowering its full-year revenue guidance to $6.2 billion-$6.25 billion, reflecting a year-over-year nominal decline of 3.2%-2.4% [33] - Adjusted gross margin for the third quarter was 60.3%, down from 61.7% in the same quarter of 2024, primarily due to pricing pressure and unfavorable product mix [29][30] Business Line Data and Key Metrics Changes - Women's health franchise revenue declined 4% in the third quarter compared to the same period in 2024, with a 9% decline in Nexplanon sales [17] - Global Nexplanon sales were $223 million in the third quarter, with a 50% decline in the U.S. and a 7% growth internationally [17][18] - The fertility business was flat in the third quarter but up 13% year-to-date, with expectations of high single-digit growth for the full year [19] - Hadlima, a biosimilar, saw a 63% increase in sales year-to-date, contributing significantly to the biosimilars segment [21] Market Data and Key Metrics Changes - The U.S. market for Nexplanon faced challenges due to unfavorable policy changes impacting budget-constrained public segments [17][18] - The respiratory business is experiencing declines, particularly in Singulair and Dulera, due to competitive pressures and mandatory price reductions [24][25] Company Strategy and Development Direction - The company remains focused on deleveraging, driving cost savings, and achieving revenue growth [12][38] - A definitive agreement was made to divest the JADA system for $440 million, which will help in faster deleveraging [20] - The company is committed to enhancing operational performance and aligning resources to strategic priorities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating current headwinds and emphasized the importance of operational excellence [10][38] - The company anticipates that the discontinuation of certain sales practices will have a significant impact on future revenue [15][19] - Management expects Nexplanon sales to be down mid to high single digits for the full year in the U.S. but anticipates international growth [18][19] Other Important Information - The independent internal investigation regarding improper sales practices has concluded, and remediation efforts are underway [9][48] - The company is not planning any additional divestitures at this time but will continue to evaluate its portfolio strategically [40] Q&A Session Summary Question: Are there opportunities for additional divestitures within the portfolio? - The company is constantly evaluating its assets but has no definitive plans for further divestitures at this time [40] Question: When should growth inflection for Vtama be expected? - Significant strides have been made to improve access, and 2026 is seen as a key year for evaluating growth trajectory [41] Question: Can you elaborate on the pressure on the respiratory business? - The respiratory business is expected to continue facing challenges due to competitive pressures and mandatory price reductions [42][43] Question: What are the expectations for Denosumab and its impact on future revenue? - The company is excited about Denosumab's launch and anticipates it will contribute positively to the biosimilars segment [54] Question: How is the CEO search progressing? - The search committee is actively working to find a permanent CEO, with no strategic changes anticipated in the interim [51]

Financial Data and Key Metrics Changes - Total revenue increased by 2% in reported dollars but decreased by 1% in constant dollars, showing an improving trend compared to the previous quarter [6][19] - Operating income reached $330 million, exceeding guidance of $260 to $290 million [6][19] - Net debt, excluding lease liabilities, decreased by $1.5 billion year-over-year, a reduction of 27% [6][23] - Adjusted earnings per share was $0.52, down from $0.60 in the same quarter last year [22] Business Line Data and Key Metrics Changes - The North Face revenue grew by 4%, with growth in both wholesale and direct-to-consumer channels [8][19] - Timberland also saw a 4% revenue increase, driven by strong demand in the Americas [10][19] - Altra experienced significant growth, with revenue up over 35% year-over-year [12] - Vans revenue declined by 11%, impacted by channel rationalization actions [19][33] Market Data and Key Metrics Changes - The Americas region revenue decreased by 1%, EMEA was flat, and APAC saw a 2% decline [19] - Direct-to-consumer sales were down 2%, while wholesale remained flat [20] Company Strategy and Development Direction - The company is focused on returning to growth and has made progress in its turnaround strategy [5][26] - Plans to divest the Dickies brand for $600 million to pay down debt and focus on core brands [7][17] - Emphasis on product innovation and marketing strategies to drive brand engagement and growth across all brands [9][10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging and unpredictable global environment but expressed confidence in the company's strategy and execution capabilities [5][26] - The company expects Q3 revenue to decline by 1% to 3% in constant dollars, with a focus on the upcoming holiday season [23][24] - Management remains optimistic about the consumer's resilience despite macroeconomic uncertainties [68] Other Important Information - The company is on track to achieve medium-term targets of $500 to $600 million in operating income expansion by fiscal 2028 and a leverage ratio of 2.5 times or below [25][26] - Free cash flow through Q2 was negative $453 million, consistent with expectations due to seasonal working capital needs [22] Q&A Session Summary Question: Path back to growth for Vans - Management indicated that increasing product newness and improved marketing strategies are key to returning Vans to growth, with expectations for better performance in upcoming quarters [31][33] Question: Gross margins and cost discipline - Management noted that gross margins were impacted by FX and lower promotions, but overall cost discipline initiatives are on track [39][42] Question: Promotional recapture and pricing strategies - Management confirmed that they are operating in a lower promotional environment and are strategically planning pricing actions for the holiday season [47][49] Question: Health of The North Face brand - Management expressed confidence in The North Face's brand health and market share opportunities, emphasizing the importance of product execution [98][100] Question: Ongoing debt deleveraging - Management is focused on achieving a leverage ratio of 2.5 times by 2028 through operational improvements and divestitures [122]

Financial Data and Key Metrics Changes - Total revenue increased by 2% in reported dollars but decreased by 1% in constant dollars, showing an improving trend compared to the previous quarter [5][18] - Operating income reached $330 million, exceeding the guidance range of $260 to $290 million [5][18] - Net debt, excluding lease liabilities, decreased by $1.5 billion year-over-year, representing a 27% reduction [5][21] - Adjusted earnings per share was $0.52, down from $0.60 in the same quarter last year [20] Business Line Data and Key Metrics Changes - The North Face revenue grew by 4%, with growth in both wholesale and direct-to-consumer channels [6][18] - Timberland also saw a 4% revenue increase, driven by strong demand in the Americas [9][18] - Altra experienced significant growth, with revenue up over 35% compared to last year [11] - Vans revenue declined by 11%, attributed to channel rationalization actions [12][18] Market Data and Key Metrics Changes - The Americas region saw a 1% revenue decline, while EMEA was flat and APAC decreased by 2% [18] - Direct-to-consumer sales were down 2%, while wholesale remained flat [19] Company Strategy and Development Direction - The company is focused on returning to growth and has made progress in its turnaround strategy, with 65% of its business by revenue now growing [5][24] - Plans to sell the Dickies brand were announced, with a sale price of $600 million, aimed at reducing debt and focusing on core brands [6][16] - The company is committed to improving brand performance and expanding market share, particularly in underdeveloped regions like the Americas [50] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain global environment but expressed confidence in the company's strategy and ability to execute [25] - The company expects Q3 revenue to decline by 1% to 3% on a constant dollar basis, with a focus on the upcoming holiday season [21][25] - There is optimism about the potential for growth in the Americas and the overall global profile of the company [50] Other Important Information - The company is working towards medium-term targets of $500 to $600 million in operating income expansion by fiscal 2028 and a leverage ratio of 2.5 times or below [24] - Free cash flow through Q2 was negative $453 million, consistent with expectations due to seasonal working capital needs [20] Q&A Session Summary Question: Can you discuss the path back to growth for Vans? - Management indicated that increasing new product offerings and enhancing marketing strategies are key to returning Vans to growth, with expectations for improved performance in upcoming quarters [28][31] Question: Can you provide more details on gross margins? - Gross margins were impacted by foreign exchange and lower promotions, with expectations for continued improvement as pricing actions take effect in Q4 [35][43] Question: What are the initial signs from retailers regarding holiday orders? - Management noted it is too early to assess retailer behavior for the holiday season but expressed optimism based on product readiness and planning [55] Question: How is the company addressing tariffs and pricing? - The company plans to implement pricing actions in Q4 to offset tariffs, with expectations to mitigate the impact by fiscal 2027 [79][80] Question: What is the outlook for debt deleveraging? - Management is confident in achieving debt reduction targets through operational improvements and the sale of non-core assets, with a focus on growing EBITDA [92][93]

Transaction Overview - Warner Bros Discovery (WBD) plans to separate its WBD Streaming & Studios (WBD S&S) business into a new publicly traded company[2] - The company is launching a cash tender and consent solicitation for its ~$35.5 billion of outstanding bonds to optimize its capital structure[2] - The tender will be funded by a $17.5 billion committed bridge facility from J P Morgan, expected to be refinanced with permanent financing[2] - WBD Global Networks (WBD GN) will retain up to 20% of WBD S&S, designed to deliver incremental cash in a future sale for further deleveraging[2] Offer Details - Up to $14.6 billion cash spend across six separate pools, funded via a 1st lien term loan from J P Morgan[7] - Investors tendering by the Early Tender Date (June 23rd) will receive an Early Tender Premium of 5 pts[7] - Pool 1 subtotal is $5.335 billion with a subcap of $3.75 billion[9] - Pool 2 subtotal is €1.5 billion with a subcap of €800 million[10] - Pool 3 subtotal is $4.968 billion with a subcap of $1 billion[11] - Pool 4 subtotal is $19.301 billion with a subcap of $8 billion[16] - Pool 5 subtotal is $946 million[20] - Pool 6 subtotal is $3.250 billion[22]